Physical symptoms comorbid with depression and the new antidepressant duloxetine

Journal of Psychosocial Nursing and Mental Health Services

Volumn 41, Issue 12, 2003, Pages 13-18

  Bailey, Katharine P ^a  

^a YALE UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 14744305524     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. th ed.). Washington, DC: Author.
2. th ed., text rev.). Washington, DC: Author.
3. Ansari, A. (2000). The efficacy of newer antidepressants in the treatment of chronic pain: A review of current literature. Harvard Review of Psychiatry, 7, 257-277.
4. Blier, P., & Abbott, F.V. (2001). Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. Journal of Psychiatry & Neuroscience, 26, 37-43.
5. Bymaster, F.P., Dreshfield-Ahmad, L.J., Threlkeld, P.G., Shaw, J.L., Thompson, L., Nelson, D.L., et al. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 25, 871-880.
6. Denninger, J.W., Mahal, Y., Merens, W., et al. (2002, May). The relationship between somatic symptoms and depression. In New Research Abstracts of the 155th annual meeting of the American Psychiatric Association (Abstract NR251, pp. 68-69). Philadelphia: American Psychiatric Association.
7. Derogatis, L.R., Lipman, R.S., Rickels, K., Uhlenhuth, E.H., & Covi, L. (1974). The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behavioral Sciences, 19, 1-15.
8. Detke, M.J., Lu, Y., Goldstein, D.J., Hayes, J.R., & Demitrack, M.A. (2002). Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. Journal of Clinical Psychiatry, 63, 308-315.
9. Dwight, M.M., Arnold, L.M., O'Brien, H., Metzger, R., Morris-Park, E., & Keck, P.E., Jr.(1998). An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics, 39, 14-17.
10. Fava, M. (2002). Somatic symptoms, depression, and antidepressant treatment. Journal of Clinical Psychiatry, 63, 305-307.
11. Fava, M., Dunner, D.L., Greist, J.H., Preskorn, S.H., Trivedi, M.H., Zajecka, J., et al. (2001). Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial. Journal of Clinical Psychiatry, 62, 413-420.
12. Frasure-Smith, N., Lesperance, F., Juneau, M., Talajic, M., & Bourassa, M.G. (1999). Gender, depression, and one-year prognosis after myocardial infarction. Psychosomatic Medicine, 61, 26-37.
13. Gallagher, R.M., & Verma, S. (1999). Managing pain and comorbid depression: A public health challenge. Seminars in Clinical Neuropsychiatry, 4, 203-220.
14. Gerber, P.D., Barrett, J.E., Barrett, J.A., Oxman, T.E., Manheimer, E., Smith, R., et al. (1992). The relationship of presenting physical complaints to depressive symptoms in primary care patients. Journal of General Internal Medicine, 7, 170-173.
15. Greden, J.F. (2003). Physical symptoms of depression: Unmet needs. Journal of Clinical Psychiatry, 64(Suppl. 7), 5-11.
16. Hudson, J.I., & Pope, H.G., Jr. (1990). Affective spectrum disorder: Does antidepressant response identify a family of disorders with a common pathophysiology? American Journal of Psychiatry, 147, 552-564.
17. Kellner, R. (1987). A symptom questionnaire. Journal of Clinical Psychiatry, 48, 268-274.
18. Kotila, M., Numminen, H., Waltimo, O., & Kaste, M. (1999). Post-stroke depression and functional recovery in a population-based stroke register. The Finnstroke study. European Journal of Neurology, 6, 309-312.
19. Kroenke, K., & Price, R.K. (1993). Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Archives of Internal Medicine, 153, 2474-2480.
20. Kroenke, K., Spitzer, R.L., Williams, J.B., Linzer, M., Hahn, S.R., deGruy, F.V., III, et al. (1994). Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Archives of Family Medicine, 3, 774-779.
21. Lynch, M.E. (2001). Antidepressants as analgesics: A review of randomized controlled trials. Journal of Psychiatry & Neuroscience, 26, 30-36.
22. Miller, L.J., & Kubes, K.L. (2002). Serotonergic agents in the treatment of fibromyalgia syndrome. Annals of Pharmacotherapy, 36, 707-712.
23. Ruoff, G.E. (1996). Depression in the patient with chronic pain. Journal of Family Practice, 43(Suppl. 6), S25-S33.
24. Sartorius, N. (2003). Physical symptoms of depression as a public health concern. Journal of Clinical Psychiatry, 64(Suppl. 7), 3-4.
25. Sartorius, N., Davidian, H., Ernberg, G., et al. (1983). Depressive disorders in different cultures. Geneva, Switzerland: World Health Organization.
26. Sellick, S.M., & Crooks, D.L. (1999). Depression and cancer: An appraisal of the literature for prevalence, detection, and practice guideline development for psychological interventions. Psychooncology, 8, 315-333.
27. Smith, D., Dempster, C., Glanville, J., Freemantle, N., & Anderson, I. (2002). Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. British Journal of Psychiatry, 180, 396-404.
28. Stahl, S.M. (1999). Why settle for silver, when you can go for the gold? Response vs. recovery as the goal of antidepressant therapy. Journal of Clinical Psychiatry, 60, 213-214.
29. Stahl, S.M. (2003). Antidepressants and somatic symptoms: Therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes. Journal of Clinical Psychiatry, 64, 745-746.
30. Tedlow, J., Fava, M., Uebelacker, L., Nierenberg, A.A., Alpert, J.E., & Rosenbaum, J. (1998). Outcome definitions and predictors in depression. Psychotherapy and Psychosomatics, 67, 266-270.
31. th ed.). New York: Churchill Livingston.
32. Wong, D.T., Bymaster, F.P., Mayle, D.A., Reid, L.R., Krushinski, J.H., & Robertson, D.W. (1993). LY248686, a new inhibitor of serotonin and noradrenaline uptake. Neuropsychopharmacology, 8, 23-33.
33. Zung, W.W.K. (1992). The role of rating scales in drug trials in depressive disorders. In M. Fava & J.F. Rosenbaum (Eds.), Research designs and methods in psychiatry (pp. 277-296), Amsterdam: Elsevier.